Chemotherapy and molecularly targeted approaches represent two very different modes of
cancer treatment and each is associated with unique benefits and limitations. Both types of …

The harm associated with lung cancer treatment include perioperative morbidity and
mortality and therapy-induced toxicities in various organs, including the heart and lungs …

Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in
Patients With Advanced Non–Small- Page 1 Randomized Phase III Trial of Erlotinib Versus …

Lung cancer is the major cause of cancer death in the world. Non Small Cell Lung Cancer
(NSCLC) accounts approximately 80-85% of all lung cancer diagnosis; the majority of …

Erlotinib-based EGFR targeted therapy has proven significant clinical improvement against
non-small cell lung cancer (NSCLC). However, the anticancer activity of Erlotinib (Ertb) is …

Tyrosine kinase inhibitors (TKi) have greatly improved the treatment and prognosis of
multiple cancer types. However, unexpected cardiotoxicity has arisen in a subset of patients …

Background Anti-depressants have been reported to own anti-tumor potential types of
cancers; however, the role of imipramine in non-small cell lung cancer (NSCLC) has not …

The gut microbiota has the potential to influence the efficacy of cancer therapy. Here, we
investigated the contribution of the intestinal microbiome on treatment outcomes in a …

This review brings forth the potential of thiazole derivatives for their anticancer activities. The
emphasis is placed on the structural diversity of thiazole derivatives, responsible for their …

PURPOSE: There is currently an ongoing paradigm shift in cancer treatment from
intravenous (IV) chemotherapeutics to oral therapies. Additionally, the increased use of long …